Bevacizumab alone or in combination with chemotherapy in glioblastomas?-Authors' reply

BELOB co-investigators

doi:10.1016/S1470-2045(14)70453-X

Bevacizumab alone or in combination with chemotherapy in glioblastomas?-Authors' reply

BELOB co-investigators

Neurology

Erasmus University Medical Centre
Erasmus University Rotterdam

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	e473-e474
Journal	The Lancet Oncology
Volume	15
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(14)70453-X
Publication status	Published - 1 Oct 2014

Bibliographical note

Funding Information:
MJvdB has done paid consultancy for Roche, AbbVie, Celldex, Amgen, and Merck Ag; has received research grants from Roche and AbbVie; and has been on the speakers’ bureau for MSD. WT declares no competing interests.

Access to Document

10.1016/S1470-2045(14)70453-X

Cite this

@article{df69a46738aa473781a3deefffdcb852,

title = "Bevacizumab alone or in combination with chemotherapy in glioblastomas?-Authors' reply",

author = "\{van den Bent\}, \{Martin J.\} and Walter Taal and \{BELOB co-investigators\}",

note = "Funding Information: MJvdB has done paid consultancy for Roche, AbbVie, Celldex, Amgen, and Merck Ag; has received research grants from Roche and AbbVie; and has been on the speakers{\textquoteright} bureau for MSD. WT declares no competing interests.",

year = "2014",

month = oct,

day = "1",

doi = "10.1016/S1470-2045(14)70453-X",

language = "English",

volume = "15",

pages = "e473--e474",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "11",

}

TY - JOUR

T1 - Bevacizumab alone or in combination with chemotherapy in glioblastomas?-Authors' reply

AU - van den Bent, Martin J.

AU - Taal, Walter

AU - BELOB co-investigators

N1 - Funding Information: MJvdB has done paid consultancy for Roche, AbbVie, Celldex, Amgen, and Merck Ag; has received research grants from Roche and AbbVie; and has been on the speakers’ bureau for MSD. WT declares no competing interests.

PY - 2014/10/1

Y1 - 2014/10/1

UR - https://www.scopus.com/pages/publications/84908120548

U2 - 10.1016/S1470-2045(14)70453-X

DO - 10.1016/S1470-2045(14)70453-X

M3 - Comment/Letter to the editor

C2 - 25281465

AN - SCOPUS:84908120548

SN - 1470-2045

VL - 15

SP - e473-e474

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -

Bevacizumab alone or in combination with chemotherapy in glioblastomas?-Authors' reply

Bibliographical note

Access to Document

Other files and links

Cite this